查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1467598

2024-2032 年按抗体类型、药物类型（贝伐单抗、利妥昔单抗、曲妥珠单抗、西妥昔单抗、帕尼单抗等）、应用、最终用户和地区分類的癌症单株抗体市场报告

Cancer Monoclonal Antibodies Market Report by Antibody Type, Medication Type (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, and Others), Application, End-User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球癌症IMARC Group抗体市场规模达466亿美元。

癌症单株抗体是指实验室生成的分子，经过改造后可模仿免疫系统对癌细胞的攻击。它可以与癌细胞表面的抗原结合併标记它们，从而触发细胞膜的破坏、阻止细胞生长和免疫系统抑制剂。它还可以直接向癌细胞提供治疗辐射以中和或消灭它们。一些最常用的单株抗体包括鼠源抗体、嵌合抗体和人源化抗体，用于治疗血液、肝癌、脑癌和乳癌。

全球癌症盛行率不断上升是推动市场成长的关键因素之一。与传统使用的非标靶疗法（例如化疗）相比，单株抗体对患者身体的副作用减少，也可用于治疗自体免疫疾病和发炎性疾病。此外，医生和肿瘤学家广泛采用具有成本效益的生物相似药单株抗体也促进了市场成长。随着基因定序和目标基因选择的技术进步，这些抗体可以被修改为具有与药物相似的特性。它们具有相同的功效，但价格比原厂药更低，这有助于提高治疗的成本效益，从而促进全球对该产品的需求不断增加。其他因素，包括对个人化药物的日益偏好、广泛的研发 (R&D) 活动以及医疗保健基础设施的显着改善，预计将进一步推动市场发展。

本报告回答的关键问题：

  • 迄今为止，全球癌症单株抗体市场表现如何，未来几年将如何表现？
  • 主要区域市场有哪些？
  • COVID-19对全球癌症单株抗体市场有何影响？
  • 根据抗体类型的市场划分是怎样的？
  • 根据药物类型分類的市场是怎么样的？
  • 基于应用程式的市场区隔是什么？
  • 基于最终用户的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球癌症单株抗体市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球癌症单株抗体市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按抗体类型

  • 鼠抗体
    • 市场走向
    • 市场预测
  • 嵌合抗体
    • 市场走向
    • 市场预测
  • 人源化抗体
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按药物类型

  • 贝伐珠单抗（阿瓦斯汀）
    • 市场走向
    • 市场预测
  • 利妥昔单抗（Rituxan）
    • 市场走向
    • 市场预测
  • 曲妥珠单抗（赫赛汀）
    • 市场走向
    • 市场预测
  • 西妥昔单抗（爱必妥）
    • 市场走向
    • 市场预测
  • 帕尼单抗（Vectibix）
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按应用

  • 乳癌
    • 市场走向
    • 市场预测
  • 血癌
    • 市场走向
    • 市场预测
  • 肝癌
    • 市场走向
    • 市场预测
  • 脑癌
    • 市场走向
    • 市场预测
  • 大肠直肠癌
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 医院和诊所
    • 市场走向
    • 市场预测
  • 药局
    • 市场走向
    • 市场预测
  • 研究实验室
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太地区
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • Roche Holding AG
    • AbbVie Inc.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • Genmab A/S
    • GlaxoSmithKline Plc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc.
    • Seattle Genetics Inc.
    • Pfizer Inc.
Product Code: SR112024A1955

The global cancer monoclonal antibodies market size reached US$ 46.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 64.6 Billion by 2032, exhibiting a growth rate (CAGR) of 3.6% during 2024-2032.

A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system's attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on antibody type, medication type, end-user and application.

Breakup by Antibody Type:

Murine Antibodies

Chimeric Antibodies

Humanized Antibodies

Others

Breakup by Medication Type:

Bevacizumab (Avastin)

Rituximab (Rituxan)

Trastuzumab (Herceptin)

Cetuximab (Erbitux)

Panitumumab (Vectibix)

Others

Breakup by Application:

Breast Cancer

Blood Cancer

Liver Cancer

Brain Cancer

Colorectal Cancer

Others

Breakup by End-User:

Hospitals and Clinics

Pharmacies

Research Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
  • What is the breakup of the market based on the antibody type?
  • What is the breakup of the market based on the medication type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer monoclonal antibodies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Antibody Type

  • 6.1 Murine Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chimeric Antibodies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Humanized Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Medication Type

  • 7.1 Bevacizumab (Avastin)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Rituximab (Rituxan)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Trastuzumab (Herceptin)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cetuximab (Erbitux)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Panitumumab (Vectibix)
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Blood Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Liver Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Brain Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Colorectal Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Research Laboratories
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Others
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Roche Holding AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AbbVie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Johnson & Johnson
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Genmab A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 GlaxoSmithKline Plc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Bristol-Myers Squibb Company
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Spectrum Pharmaceuticals Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Seattle Genetics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Pfizer Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2023
  • Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2023
  • Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2023
  • Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million US$), 2024-2032
  • Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million US$), 2024-2032
  • Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players